Интересно посмотреть на продажу Abbott Laboratories от 44.50$
ที่อัปเดต:
Новость:
Patients who received Abbott Laboratories' novel dissolving vascular stent had a significantly higher rate of serious adverse heart events than those treated with the company's widely used Xience drug-coated metal stent two years after implantation, according to data presented on Saturday.
The U.S. Food and Drug Administration said it was informing healthcare providers of the increased rate of major adverse cardiac events observed in patients receiving Absorb in the study. The agency said it will continue to monitor Absorb's performance in clinical studies and reports submitted to it.
Источник By Bill Berkrot | WASHINGTON:
reuters.com/article/us-heart-abbott-stent-idUSKBN16P0IV?type=companyNews
Patients who received Abbott Laboratories' novel dissolving vascular stent had a significantly higher rate of serious adverse heart events than those treated with the company's widely used Xience drug-coated metal stent two years after implantation, according to data presented on Saturday.
The U.S. Food and Drug Administration said it was informing healthcare providers of the increased rate of major adverse cardiac events observed in patients receiving Absorb in the study. The agency said it will continue to monitor Absorb's performance in clinical studies and reports submitted to it.
Источник By Bill Berkrot | WASHINGTON:
reuters.com/article/us-heart-abbott-stent-idUSKBN16P0IV?type=companyNews
การซื้อขายยังคงดำเนินอยู่
ปิดการเทรด: ถึงเป้าหมายการทำกำไร
คำจำกัดสิทธิ์ความรับผิดชอบ
ข้อมูลและบทความไม่ได้มีวัตถุประสงค์เพื่อก่อให้เกิดกิจกรรมทางการเงิน, การลงทุน, การซื้อขาย, ข้อเสนอแนะ หรือคำแนะนำประเภทอื่น ๆ ที่ให้หรือรับรองโดย TradingView อ่านเพิ่มเติมที่ ข้อกำหนดการใช้งาน